SCHEMBL2189697

SCHEMBL2189697

CC(C)([C@@H]1CCN(c2ccc(C(F)(F)F)nc2)C(=O)C1)S(=O)(=O)c1cc(F)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.43
CYP3A4 P08684 4/20 0.39
CACNA1B Q00975 2/20 0.39
NR1I2 O75469 1/20 0.39
PSEN1 P49768 3/20 0.36
PSEN2 P49810 3/20 0.36
APH1B Q8WW43 3/20 0.36
NCSTN Q92542 3/20 0.36
APH1A Q96BI3 3/20 0.36
PSENEN Q9NZ42 3/20 0.36
PTGS1 P23219 1/20 0.36
NR1H2 P55055 4/20 0.34
NR1H3 Q13133 4/20 0.34
GPR119 Q8TDV5 2/20 0.34
NOX4 Q9NPH5 1/20 0.34
SLC6A9 P48067 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2187292 1.00 DPP4 (0.43) DPP4CYP3A4CACNA1BNR1I2PSEN1
SCHEMBL2188879 0.89 CYP3A4 (0.47) DPP4CYP3A4CACNA1BNR1I2KMT2A
SCHEMBL2189754 0.89 CYP3A4 (0.47) DPP4CYP3A4CACNA1BNR1I2KMT2A
SCHEMBL2188117 0.84 PKM (0.40) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2193112 0.84 PKM (0.40) CYP3A4CACNA1BNR1I2NR1H2NR1H3
SCHEMBL2190694 0.80 CACNA1B (0.42) DPP4CYP3A4CACNA1B
SCHEMBL2191470 0.80 CACNA1B (0.42) DPP4CYP3A4CACNA1B
SCHEMBL12415654 0.79 DPP4 (0.45) DPP4CYP3A4CACNA1BNR1I2PSEN1
SCHEMBL2191232 0.79 DPP4 (0.45) DPP4CYP3A4CACNA1BNR1I2PSEN1
SCHEMBL2189802 0.79 DPP4 (0.45) DPP4CYP3A4CACNA1BNR1I2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D DPP4 604/4885CYP3A4 939/4885CACNA1B 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.